Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis.
| Title: | Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. |
|---|---|
| Authors: | Collet TH; Service of Endocrinology, Diabetes, and Metabolism (T.-H.C.), University Hospital of 1011 Lausanne, Switzerland; Department of Ambulatory Care and Community Medicine (T.-H.C., J.C.), University of Lausanne, 1011 Lausanne, Switzerland; Departments of Epidemiology and Biostatistics (D.C.B., E.V.) and Medicine (D.C.B.), University of California, San Francisco, San Francisco, California 94143; Division of Endocrinology, Diabetes, and Metabolism (A.R.C.), Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; Department of Public Health (B.O.Å.), Norwegian University of Science and Technology, N-7491 Trondheim, Norway; Department of Endocrinology (B.O.Å.), St Olavs Hospital, Trondheim University Hospital, N-7006 Trondheim, Norway; Department of General Internal Medicine (S.W., D.A., N.R.), Inselspital, University of Bern, 3000 Bern, Switzerland; Department of Clinical Pharmacology and Toxicology (S.W.), University Hospital of Zürich, 8091 Zürich, Switzerland; Department of Public Health and Primary Care (J.G., W.P.J.d.E.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands; School of Population Health (A.B.) and School of Medicine and Pharmacology (J.P.W.), The University of Western Australia, Crawley, and Department of Endocrinology and Diabetes (J.P.W.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Division of Endocrinology (R.M.B.M., J.A.S.), Department of Medicine, Federal University of Sao Paulo, 04023-900 São Paulo, Brazil; Department of Endocrinology (M.P.J.V.), Royal Free Hospital, London NW3 2PF, United Kingdom; Clinic for Internal Medicine B (M.D.) and Institute of Clinical Chemistry and Laboratory Medicine (H.W.), University Medicine Greifswald, and Institute for Community Medicine (H.V.), Study of Health in Pomerania/Clinical-Epidemiological Research, University of Greifswald, D-17487 Greifswald, Germany; DZHK (German Centre for Cardiovascular Research) (M.D.,; Bauer DC; Cappola AR; Asvold BO; Weiler S; Vittinghoff E; Gussekloo J; Bremner A; den Elzen WP; Maciel RM; Vanderpump MP; Cornuz J; Dörr M; Wallaschofski H; Newman AB; Sgarbi JA; Razvi S; Völzke H; Walsh JP; Aujesky D; Rodondi N |
| Corporate Authors: | Thyroid Studies Collaboration |
| Source: | The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2014 Sep; Vol. 99 (9), pp. 3353-62. Date of Electronic Publication: 2014 Jun 10. |
| Publication Type: | Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2017- : New York : Oxford University Press; Original Publication: Springfield, Ill. : Charles C. Thomas |
| MeSH Terms: | Autoantibodies/*blood ; Coronary Disease/*epidemiology ; Hypothyroidism/*epidemiology; Autoantibodies/immunology ; Coronary Disease/mortality ; Hypothyroidism/immunology ; Hypothyroidism/mortality ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Prevalence ; Prognosis ; Risk Factors ; Seroepidemiologic Studies ; Severity of Illness Index ; Young Adult |
| Abstract: | Context: Subclinical hypothyroidism has been associated with increased risk of coronary heart disease (CHD), particularly with thyrotropin levels of 10.0 mIU/L or greater. The measurement of thyroid antibodies helps predict the progression to overt hypothyroidism, but it is unclear whether thyroid autoimmunity independently affects CHD risk.; Objective: The objective of the study was to compare the CHD risk of subclinical hypothyroidism with and without thyroid peroxidase antibodies (TPOAbs).; Data Sources and Study Selection: A MEDLINE and EMBASE search from 1950 to 2011 was conducted for prospective cohorts, reporting baseline thyroid function, antibodies, and CHD outcomes.; Data Extraction: Individual data of 38 274 participants from six cohorts for CHD mortality followed up for 460 333 person-years and 33 394 participants from four cohorts for CHD events.; Data Synthesis: Among 38 274 adults (median age 55 y, 63% women), 1691 (4.4%) had subclinical hypothyroidism, of whom 775 (45.8%) had positive TPOAbs. During follow-up, 1436 participants died of CHD and 3285 had CHD events. Compared with euthyroid individuals, age- and gender-adjusted risks of CHD mortality in subclinical hypothyroidism were similar among individuals with and without TPOAbs [hazard ratio (HR) 1.15, 95% confidence interval (CI) 0.87-1.53 vs HR 1.26, CI 1.01-1.58, P for interaction = .62], as were risks of CHD events (HR 1.16, CI 0.87-1.56 vs HR 1.26, CI 1.02-1.56, P for interaction = .65). Risks of CHD mortality and events increased with higher thyrotropin, but within each stratum, risks did not differ by TPOAb status.; Conclusions: CHD risk associated with subclinical hypothyroidism did not differ by TPOAb status, suggesting that biomarkers of thyroid autoimmunity do not add independent prognostic information for CHD outcomes. |
| References: | J Clin Endocrinol Metab. 2002 Jul;87(7):3221-6. (PMID: 12107228); J Clin Endocrinol Metab. 1990 Sep;71(3):661-9. (PMID: 2168432); Arch Intern Med. 2012 May 28;172(10):799-809. (PMID: 22529182); J Clin Endocrinol Metab. 2012 Nov;97(11):3944-50. (PMID: 22879629); JAMA. 2006 Mar 1;295(9):1033-41. (PMID: 16507804); Clin Trials. 2005;2(3):209-17. (PMID: 16279144); J Clin Endocrinol Metab. 2008 May;93(5):1751-7. (PMID: 18270254); J Clin Endocrinol Metab. 2006 Dec;91(12):5076-82. (PMID: 16968790); JAMA. 2001 May 16;285(19):2486-97. (PMID: 11368702); Thyroid. 1996 Jun;6(3):155-60. (PMID: 8837320); J Clin Endocrinol Metab. 2002 Feb;87(2):489-99. (PMID: 11836274); Lancet. 2009 Mar 28;373(9669):1083-96. (PMID: 19299006); Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68. (PMID: 7641412); Eur J Endocrinol. 2010 Mar;162(3):569-77. (PMID: 19966035); Biometrics. 2001 Mar;57(1):114-9. (PMID: 11252585); Ann Intern Med. 2000 Feb 15;132(4):270-8. (PMID: 10681281); JAMA. 2010 Sep 22;304(12):1365-74. (PMID: 20858880); Clin Endocrinol (Oxf). 2012 Dec;77(6):911-7. (PMID: 22724581); Thyroid. 2001 Aug;11(8):757-64. (PMID: 11525268); Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003419. (PMID: 17636722); J Clin Endocrinol Metab. 1990 Sep;71(3):553-8. (PMID: 2203796); J Clin Endocrinol Metab. 2013 Jun;98(6):2308-17. (PMID: 23539723); Arch Intern Med. 2008 Mar 24;168(6):587-92. (PMID: 18362250); Endocr Pract. 2012 Nov-Dec;18(6):988-1028. (PMID: 23246686); BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563); Endocrine. 2004 Jun;24(1):1-13. (PMID: 15249698); J Clin Endocrinol Metab. 2012 Jun;97(6):1962-9. (PMID: 22438233); JAMA. 2004 Jan 14;291(2):228-38. (PMID: 14722150); BMC Cardiovasc Disord. 2010 May 28;10:22. (PMID: 20509904); Ann Intern Med. 2008 Jun 3;148(11):832-45. (PMID: 18490668); J Clin Endocrinol Metab. 2004 Oct;89(10):4890-7. (PMID: 15472181); J Clin Endocrinol Metab. 2010 Mar;95(3):1095-104. (PMID: 20097710); J Clin Endocrinol Metab. 2013 Jun;98(6):2267-9. (PMID: 23633199); BMJ. 2010 Feb 05;340:c221. (PMID: 20139215); Thyroid. 2005 Mar;15(3):279-85. (PMID: 15785248); Eur J Endocrinol. 2010 Mar;162(3):579-85. (PMID: 20007334); Circulation. 2012 Aug 28;126(9):1040-9. (PMID: 22821943); Arch Intern Med. 2005 Nov 28;165(21):2467-72. (PMID: 16314542); J Clin Endocrinol Metab. 2013 Feb;98(2):533-40. (PMID: 23162099); BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) |
| Grant Information: | R01 HL075366 United States HL NHLBI NIH HHS; N01-HC-80007 United States HC NHLBI NIH HHS; K24 AR051895 United States AR NIAMS NIH HHS; R01 HL-075366 United States HL NHLBI NIH HHS; N01-HC-85086 United States HC NHLBI NIH HHS; AG-027058 United States AG NIA NIH HHS; N01 HC-55222 United States HC NHLBI NIH HHS; N01 HC055222 United States HL NHLBI NIH HHS; N01-HC-85079 United States HC NHLBI NIH HHS; U01HL080295 United States HL NHLBI NIH HHS; P30 AG024827 United States AG NIA NIH HHS; R01 AG-15928 United States AG NIA NIH HHS; R01 AG015928 United States AG NIA NIH HHS; U01 HL080295 United States HL NHLBI NIH HHS; N01 HC015103 United States HC NHLBI NIH HHS; N01 HC085086 United States HL NHLBI NIH HHS; P30-AG-024827 United States AG NIA NIH HHS; AG-032317 United States AG NIA NIH HHS; N01 HC085079 United States HL NHLBI NIH HHS; N01 HC-75150 United States HC NHLBI NIH HHS; R01 AG-20098 United States AG NIA NIH HHS; R01 AG020098 United States AG NIA NIH HHS; R01 AG032317 United States AG NIA NIH HHS; N01 HC075150 United States HL NHLBI NIH HHS; R01 AG023629 United States AG NIA NIH HHS; R01 AG027058 United States AG NIA NIH HHS; N01 HC045133 United States HC NHLBI NIH HHS; N01 HC035129 United States HC NHLBI NIH HHS; R56 AG023629 United States AG NIA NIH HHS |
| Substance Nomenclature: | 0 (Autoantibodies) |
| Entry Date(s): | Date Created: 20140611 Date Completed: 20150112 Latest Revision: 20250529 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC4154087 |
| DOI: | 10.1210/jc.2014-1250 |
| PMID: | 24915118 |
| Database: | MEDLINE |
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't